The AKR1C3 inhibitor tolfenamic acid (Endo et al., 2011) and siRNA treatment increase the sensitivity of non-resistant PCa cells to docetaxel (DTX), suggesting a role of AKR1C3 in DTX resistance (Shen et al., 2011). This evidence concerns the gene AKR1C3 and posterior cortical atrophy.